These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37435731)

  • 21. Molecular interactions and inhibition of the SARS-CoV-2 main protease by a thiadiazolidinone derivative.
    Andrzejczyk J; Jovic K; Brown LM; Pascetta VG; Varga K; Vashisth H
    Proteins; 2022 Nov; 90(11):1896-1907. PubMed ID: 35567429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
    Hicks EG; Kandel SE; Lampe JN
    Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primer for Designing Main Protease (M
    Thakur A; Sharma G; Badavath VN; Jayaprakash V; Merz KM; Blum G; Acevedo O
    J Phys Chem Lett; 2022 Jun; 13(25):5776-5786. PubMed ID: 35726889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
    Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
    Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
    Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF
    J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals.
    Xu YS; Chigan JZ; Li JQ; Ding HH; Sun LY; Liu L; Hu Z; Yang KW
    Bioorg Chem; 2022 Jul; 124():105799. PubMed ID: 35462235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
    Deodato D; Asad N; Dore TM
    Bioorg Med Chem Lett; 2022 Sep; 72():128867. PubMed ID: 35760254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation.
    Mahgoub RE; Mohamed FE; Alzyoud L; Ali BR; Ferreira J; Rabeh WM; AlNeyadi SS; Atatreh N; Ghattas MA
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings.
    Dong J; Varbanov M; Philippot S; Vreken F; Zeng WB; Blay V
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):24-35. PubMed ID: 36305272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.
    Guo S; Xie H; Lei Y; Liu B; Zhang L; Xu Y; Zuo Z
    Bioorg Chem; 2021 May; 110():104767. PubMed ID: 33667900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel inhibitors of SARS-CoV-2 main protease.
    Zheng L; Chen Y; Bao J; He L; Dong S; Qi Y; Zhang JZH
    J Biomol Struct Dyn; 2022; 40(23):12526-12534. PubMed ID: 34472424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.